Core Viewpoint - Green Leaf Pharmaceutical (02186) has seen a nearly 3% increase in stock price, attributed to the successful inclusion of five new products in the National Medical Insurance Drug List for 2025 and the Commercial Health Insurance Innovative Drug List for 2025 [1] Group 1: Product Inclusion - Five new products from Green Leaf Pharmaceutical have been successfully included in the National Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List for 2025 [1] - The new products include: - Mimesin (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai (Paliperidone Palmitate Injection (II)) which are newly included in the National Medical Insurance Drug List [1] - Zanbija (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug List [1] - Baituo Wei® (Injectable Goserelin Microspheres) and Ruiketuo (Injectable Risperidone Microspheres (II)) have successfully renewed their contracts and continue to be included in the National Medical Insurance Drug List [1]
港股异动 | 绿叶制药(02186)涨近3% 米美欣®等五款新品获纳入国家医保药品目录或商保创新药目录